NCT00888043 Clinical Trial Information | SourceSolution's Biotech, Pharma, CMO, CRO Directory

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors


Sponsors: Duke University Centocor, Inc. Genentech	Phases: Phase I
Indications	Acronym: CNTO95/Avastin
Solid Tumors
Age Groups: Adult Senior	Gender: Both
Names: Drug: CNTO 95 and avastin	Enrollment: 54

Additional information about NCT00888043.